Abstract:Objective: To identify a cognitive composite that is sensitive to tracking preclinical Alzheimer's disease decline to be used as a primary end point in treatment trials. Method: We capitalized on longitudinal data collected from 1995 to 2010 from cognitively unimpaired presenilin 1 (PSEN1) E280A mutation carriers from the world's largest known early-onset autosomal dominant Alzheimer's disease kindred to identify a composite cognitive test with the greatest statistical power to track preclinical Alzheimer's disease decline and estimate the number of carriers age 30 years and older needed to detect a treatment effect in the Alzheimer's Prevention Initiative's (API) preclinical Alzheimer's disease treatment trial. The mean-to-standard-deviation ratios (MSDRs) of change over time were calculated in a search for the optimal combination of 1 to 7 cognitive tests/subtests drawn from the neuropsychological test battery in cognitively unimpaired mutation carriers during a 2- and 5-year follow-up period (n = 78 and 57), using data from noncarriers (n = 31 and 56) during the same time period to correct for aging and practice effects. Combinations that performed well were then evaluated for robustness across follow-up years, occurrence of selected items within top-performing combinations, and representation of relevant cognitive domains.Results: The optimal test combination included Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Word List Recall, CERAD Boston Naming Test (high frequency items), Mini-Mental State Examination (MMSE) Orientation to Time, CERAD Constructional Praxis, and Raven's Progressive Matrices (Set A), with an MSDR of 1.62. This composite is more sensitive than using either the CERAD Word List Recall (MSDR = 0.38) or the entire CERAD-Col battery (MSDR = 0.76). A sample size of 75 cognitively normal PSEN1 E280A mutation carriers aged 30 years and older per treatment arm allows for a detectable treatment effect of 29% in a 60-month trial (80% power, P = .05).Conclusions: We have identified a composite cognitive test score representing multiple cognitive domains that, compared to the most sensitive single test item, has improved power to track preclinical Alzheimer's disease decline in autosomal dominant Alzheimer's disease mutation carriers and to evaluate preclinical Alzheimer's disease treatments. This API composite cognitive test score will be used as the primary end point in the first API trial in cognitively unimpaired autosomal dominant Alzheimer's disease carriers within 15 years of their estimated age at clinical onset. We have independently confirmed our findings in a separate cohort of cognitively healthy older adults who progressed to the clinical stages of late-onset Alzheimer's disease, described in a separate report, and continue to refine the composite in independent cohorts and compared with other analytic approaches. (C) Copyright 2014 Physicians Postgraduate Press, Inc.

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease

[IC‐P‐041]: SAMPLE SIZES FOR 24‐MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID‐POSITIVE ADULTS

SAMPLE SIZES FOR 24-MONTH ALZHEIMER’S PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID-POSITIVE ADULTS

[O5–01–04]: SAMPLE SIZES FOR 24‐MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID‐POSITIVE ADULTS

Sample Size Estimates for Pre-Symptomatic Alzheimer's Disease Treatment/surrogate Marker Development Trials in Apolipoprotein E4 Homozygotes Close to Their Estimated Age at Symptomatic Onset

P4–066: Alzheimer's Disease Biomarkers As Outcome Measures for Clinical Trials

Design and sample size considerations for Alzheimer’s disease prevention trials using multistate models

Simulation‐based effect size analysis in the absence of drug effects to inform the design of clinical trials in Alzheimer’s disease

Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease

Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN)

15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN

Alzheimer Disease Biomarkers as Outcome Measures for Clinical Trials in MCI.

Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study.

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring

Quantitative Amyloid Imaging In Autosomal Dominant Alzheimer'S Disease: Results From The Dian Study Group

The Bio-Hermes Study: Biomarker database developed to investigate blood-based and digital biomarkers in community-based, diverse populations clinically screened for Alzheimer's disease

New Therapeutics in Alzheimer's Disease Longitudinal Cohort study (NTAD): study protocol

Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

The Alzheimer'S Prevention Initiative Composite Cognitive Test Score: Sample Size Estimates For The Evaluation Of Preclinical Alzheimer'S Disease Treatments In Presenilin 1 E280a Mutation Carriers

Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease